VuKBusaidyNCabanillasME. A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2012;12
(5):355–362.
2.
PanJChenCJinY. Differential impact of structurally different anti-diabetic drugs on proliferation and chemosensitivity of acute lymphoblastic leukemia cells. Cell Cycle. 2012;11
(12):2314–2326.
3.
GrimaldiCChiariniFTabelliniG. AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. Leukemia. 2012;26
(1):91–100.
4.
LeclercGMLeclercGJKuznetsovJN. Metformin induces apoptosis through AMPK-dependent inhibition of UPR signaling in ALL lymphoblasts. PLoS One. 2013;8
(8):e74420.
ZadikZEstrovZKarovY. The effect of growth hormone and IGF-I on clonogenic growth of hematopoietic cells in leukemic patients during active disease and during remission—a preliminary report. J Pediatr Endocrinol. 1993;6
(1):79–83.
7.
YamadaHIijimaKTomitaO. Effects of insulin-like growth factor-1 on B-cell precursor acute lymphoblastic leukemia. Int J Hematol. 2013;97
(1):73–82.
8.
GreenASChapuisNMacielTT. The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation. Blood. 2010;116
(20):4262–4273.
9.
RosilioCBen-SahraIBostF. Metformin: a metabolic disruptor and anti-diabetic drug to target human leukemia. Cancer Lett. 2014;346(2):188–196.
